Latest Healthcare News

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

Decidr AI Industries has announced a strategic acquisition of Delaware-based Sugarwork Inc., marking its official entry into the US market and enhancing its Agentic AI platform with advanced knowledge transfer capabilities.

Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.

EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its Dyspro and Libbo therapies.

Visionflex Group Limited has successfully passed all resolutions at its 2025 Annual General Meeting, reinforcing its governance framework and capital strategy.

Regis Healthcare reported robust FY25 financial results and outlined ambitious expansion plans targeting 10,000 beds by FY28, while urging urgent government reforms to address the sector’s undersupply of quality aged care.

Pro Medicus Limited’s U.S. arm has secured a significant five-year, A$44 million contract to deploy its cloud-based Visage 7 imaging platform with Advanced Radiology Management, marking a strategic expansion in North America.

Radiopharm Theranostics has reached the halfway mark in enrolling patients for its Phase 2b trial of RAD101, a novel imaging agent targeting brain metastases. Early data suggest RAD101 may outperform MRI in distinguishing tumor recurrence from radiation damage.

Bioxyne Limited is expanding its footprint with a new UK GMP-certified medicinal cannabis manufacturing site, backed by £850,000 in funding from South of Scotland Enterprise. This move positions the company to tap into the UK’s growing medicinal cannabis market, the second largest in Europe.

Alcidion Group has expanded its contract with Leidos Australia, adding $12.3 million in value and increasing annual recurring revenue by $2.5 million through to 2028.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payable to ASX CDI holders, impacting the Australian dollar amount investors will receive.

Navigator Global Investments delivered record financial results in FY25, driven by strong revenue growth and strategic expansion, while suspending dividends to fuel future growth. Key leadership changes mark a new chapter for the alternative asset manager.